Search Results
16 results found-
This means information that a reasonable person would expect to have a material effect on the price or value of CSL's securities, being any information that would, or would be likely to, influence persons who commonly invest in securities in deciding whether or not to subscribe for, buy or sell those securities.
https://www.csl.com/-/media/shared/documents/one-csl/csl-governance-docs/continuous-disclosure-policy.pdf -
i) are solely related to over-the-counter medicines
https://www.csl.com/-/media/shared/documents/vifor-methodological-note-2025-ireland---final-180626.pdf -
Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia - Sep 24, 2024
Zeria expects to begin to market Veltassa ® following National Health Insurance price listing.
https://newsroom.csl.com/2024-09-24-Veltassa-R-patiromer-approved-in-Japan-for-the-treatment-of-adults-with-hyperkalemia -
Ordinary commercial transactions, including discounts, price reductions, rebates and trading-related mechanisms
https://www.csl.com/-/media/shared/documents/seqirus-disclosures/new-disclosures/seqirus_method_2025_efpia.pdf -
Ordinary commercial transactions, including discounts, price reductions, rebates and trading-related mechanisms
https://www.csl.com/-/media/shared/documents/seqirus-disclosures/new-disclosures/seqirus_method_2025_spain_en.pdf -
Ordinary commercial transactions, including discounts, price reductions, rebates and trading-related mechanisms
https://www.csl.com/-/media/shared/documents/seqirus-disclosures/new-disclosures/seqirus_method_2025_italy_en.pdf -
Ordinary commercial transactions, including discounts, price reductions, rebates and trading-related mechanisms
https://www.csl.com/-/media/shared/documents/seqirus-disclosures/new-disclosures/seqirus_method_2025_sweden.pdf -
Ordinary commercial transactions, including discounts, price reductions, rebates and trading-related mechanisms
https://www.csl.com/-/media/shared/documents/seqirus-disclosures/new-disclosures/seqirus_method_2025_germany.pdf -
TOVs solely related to over-the-counter medicines
https://www.csl.com/-/media/shared/documents/cslviforireland_method_2024.pdf -
ToVs solely related to over-the-counter medicines - ToVs excluded from the scope of the EFPIA Disclosure Code, such as informational and educational materials, items of medical utility, food and beverage, medical samples - Fees charged by logistics agencies assisting in organising travel and meetings
https://www.csl.com/-/media/shared/documents/vifor-disclosures/tov/2024_methodologicalnote_switzerland_draft.pdf